Observational, prospective study evaluating the safety and efficacy of Tetrahydrocannabinol/cannabidiol oromucosal spray (Sativex) in patients with Multiple Sclerosis: A real world Study

Trial Profile

Observational, prospective study evaluating the safety and efficacy of Tetrahydrocannabinol/cannabidiol oromucosal spray (Sativex) in patients with Multiple Sclerosis: A real world Study

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs Nabiximols (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top